Key result
BAY 60-2770 cuts myocardial infarct size by ~66% and improves LV function in rat hearts.
Why the study?
The molecular mechanism and cardioprotective effects of the sGC activator BAY 60-2770 in cardiac ischemia-reperfusion injury had not been assessed.
Does BAY 60-2770 reduce infarct size and improve left ventricular function in ischemia-reperfusion-injured rat hearts?
Does BAY 60-2770 reduce infarct size and improve left ventricular function in ischemia-reperfusion-injured rat hearts?
The sGC activator BAY 60-2770 protects against cardiac ischemia-reperfusion injury by opening mitoKATP channels and reducing mitochondrial ROS via PKG activation.
Soluble guanylate cyclase (sGC) has been suggested as a therapeutic target for cardiac ischemia-reperfusion (IR) injury. Until now, the molecular mechanism of BAY 60-2770, a sGC activator, in cardiac IR injury has not been assessed. To identify the cardioprotective effects of BAY 60-2770 in IR-injured rat hearts, IR injury was established by occlusion of LAD for 40 min and reperfusion for 7 days, and the effects of BAY 60-2770 on myocardial protection were assessed by echocardiography and TTC staining. 5 nM and 5 μM of BAY 60-2770 were perfused into isolated rat hearts in a Langendorff system. After 10- or 30-min reperfusion with BAY 60-2770, cGMP and cAMP concentrations and PKG activation status were examined. Hearts were also perfused with 1 μM KT5823 or 100 μM 5-HD in conjunction with 5 nM Bay 60-2770 to evaluate the protective role of PKG. Mitochondrial oxidative stress was investigated under hypoxia-reoxygenation in H9c2 cells. In IR-injured rat hearts, BAY 60-2770 oral administration reduced infarct size by TTC staining and improved left ventricular function by echocardiography. Tissue samples from BAY 60-2770-perfused hearts had approximately two-fold higher cGMP levels. BAY 60-2770 increased PKG activity in the myocardium, and the reduced infarct area by BAY 60-2770 was abrogated by KT-5823 in isolated myocardium. In H9c2 cardiac myoblasts, hypoxia-reoxygenation-mediated mitochondrial ROS generation was diminished with BAY 60-2770 treatment, but was recovered by pretreatment with KT-5823. BAY 60-2770 demonstrated a protective effect against cardiac IR injury via mitoKATP opening and decreased mitoROS by PKG activation. BAY 60-2770 has a protective effect against cardiac IR injury via mitoKATP opening and decreased mitoROS by PKG activation. These results demonstrated that BAY 60-2770 may be used as a therapeutic agent for cardiac IR injury.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2017) studied Myocardial ischemia-reperfusion injury (n=36). BAY 60-2770 vs. Vehicle / Ischemia-reperfusion without treatment was evaluated on Infarct size by TTC staining (p=<0.05). BAY 60-2770 significantly reduced myocardial infarct size to 17.91% compared to 53.08% in the control group and improved left ventricular function in ischemia-reperfusion-injured rat hearts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: